Recommendations on vaccine and treatment evaluation

WHO produces a number of recommendations on how to best design, conduct and analyze trial designs for key priority pathogens, driven by the needs highlighted in the roadmaps and target product profiles and based on the current epidemiological knowledge. 

Recommendations and generic protocols to evaluate a therapeutic or a vaccine are developed when products are about to be tested in a Phase 3 trial. Recommendations for Zika, Lassa, Ebola, and MERS-CoV are available and generic protocols are available for Lassa treatment evaluation and Zika vaccine evaluation as well as protocols for COVID-19 therapeutics and vaccines. It is recognized that recommendations are likely to evolve as new evidence is generated and that they must be tailored to the social and cultural context of affected communities.